Topokine Therapeutics

Allergan Acquires Topokine Therapeutics

Allergan has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction. Under the terms of the agreement, Allergan purchased Topokine Therapeutics for an up-front payment of $85 million and success-based development and sales milestones for XAF5, Topokine’s topical agent in late-stage development for the treatment of steatoblepharon.

Unpacking Undereye Bags

Topokine begins late-stage trials of XAF5 for topical reduction of steatoblepharon.
Unpacking Undereye Bags

It was an accident, really. Michael Singer, MD, ophthalmologist and instructor of pharmacology at Harvard University, and Murat Kalayoglu, MD, ophthalmologist and researcher with expertise in lipid metabolism, were investigating XAF5, an experimental prostaglandin ointment originally developed at Harvard University for the treatment of glaucoma. As patients used the eye drops meant to decrease eye pressure, they and their doctors began to notice prostaglandin-associated periorbitopathy (PAP), a side effect that had been documented with other prostaglandin treatments.

Late-Stage Trial Initiated for Topical Reduction of Undereye Bags

Late-Stage Trial Initiated for Topical Reduction of Undereye Bags

Biotechnology company Topokine Therapeutics has initiated a Phase 2b/3 study of its lead product, XAF5 Ointment, for the reduction of steatoblepharon (undereye bags). Applied to the lower eyelids once nightly, the topical treatment penetrates the skin and acts pharmacologically on fat cells to shrink eye bags as an alternative to blepharoplasty surgery.